Enquirer Consulting Group

Reachable Buyer Map

Prepared for Stan Watowich · Ridgeline Therapeutics · August 2026
Straight about the shape first. A preclinical asset does not have a customer market. It has a short list of seats that evaluate, fund and license, and that list is smaller than most markets and harder to reach, because the people on it are not registered anywhere and do not answer publication traffic. This map is who those seats are, which companies they sit in, and roughly how many there are. It describes the market rather than your business, and there is nothing to buy at the end of it.
Large and mid-cap pharma with a cardiometabolic franchise
The obvious home for an oral small molecule that touches energy metabolism, and the group that keeps standing search teams whose entire job is this. Small enough to cover completely by name, which is the whole point of putting it first.
Who signs: head of search and evaluation, VP business development and licensing, therapeutic area head, head of external innovation or scientific partnering.
Roughly 40 to 60 companies
worldwide, of which around half run a US-based search and evaluation function that can be reached without a time zone
Specialty pharma in musculoskeletal, neuromuscular and rare disease
Where muscular dystrophy and frailty indications get treated as a franchise rather than as an aging story. Smaller balance sheets, faster decisions, and noticeably more willingness to look at something preclinical than the first group has.
Who signs: chief business officer, head of business development, chief scientific officer, and at the smaller companies the chief executive directly.
70 to 110
US and European specialty pharmaceutical companies carrying a named musculoskeletal, neuromuscular or rare disease franchise
Biotechs in metabolic, obesity and muscle biology
Not licensees so much as the comparison set, the co-development route and occasionally the merger. Their business people track the same target space you do, and the introduction that matters is often theirs to make rather than yours.
Who signs: chief executive, chief business officer, chief scientific officer, VP corporate development.
250 to 350
US clinical and preclinical stage companies with a publicly disclosed metabolic, obesity or skeletal muscle program
Venture and corporate venture
Two different animals under one label. Independent funds buy a thesis and a team. Pharma venture arms buy an early option on a molecule the parent may want later, and they sit down the corridor from the search teams in the first segment, which makes them the shortest route into a company that is not returning calls.
Who signs: partner or principal on the therapeutics side, and at corporate arms the investment director who reports into strategy rather than into finance.
Roughly 350 to 450 active US therapeutics investors
of which somewhere around 30 to 45 are pharmaceutical corporate venture arms; the smaller half is the more useful half here
Disease foundations and non-dilutive funders
Slower money and better doors. A foundation funding frailty, sarcopenia or muscular dystrophy work also convenes the clinicians, the registries and the industry people who follow that indication, so the funding is frequently worth less than the room it arrives with.
Who signs: chief scientific officer, research program director, head of venture philanthropy.
60 to 90
US foundations and non-profit funders active in aging, musculoskeletal and metabolic disease
Pharma outside the US with an aging mandate
Japanese and Korean companies live inside the demographic that sarcopenia and frailty describe, and several treat it as a named strategic area rather than an emerging one. Chronically under-approached from the US, because the search function sits at headquarters and does not travel to the meetings you would meet it at.
Who signs: head of global search and evaluation, regional business development lead, licensing director.
Roughly 25 to 40 companies
Japanese, Korean and European pharmaceutical companies with a declared interest in aging, sarcopenia or musculoskeletal decline; interest is self-declared and not registered anywhere

Where the openings are

1
This is a named-account problem, not a volume one. Everything on this page comes to between eight hundred and eleven hundred organizations, and the pharma and biotech companies inside that, the ones that could actually license an asset like this, come to fewer than six hundred. That is small enough to cover completely, by name, with a real message written for each one. It is also far too small for anything that depends on being found.
2
The seat that says yes does not read the paper. Search and evaluation is a standing function with a mandate, a therapeutic remit and a review calendar. Publications and conference talks reach scientists, and scientists forward things when they happen to remember. The evaluation seat has a job description that is literally to find assets like yours this quarter, and nothing currently routes you to it.
3
None of these roles sit in a public register. Companies are registered. Business development seats, therapeutic remits and who currently owns metabolic search are not, and they move constantly. That is exactly why the segment stays open: it takes identification rather than a list anyone can buy, and identification is mechanical work that a small company never has the hours to staff.
4
Coverage has a window. Portfolio reviews and partnering meetings run on a cycle. Being in front of the right forty people in the weeks before a review is a different outcome from standing in a partnering room during one, and the difference between the two is scheduling and record keeping rather than science.
Built from public registries and public company disclosures, counts banded deliberately. Business development, licensing and search seats are not recorded in any public register, so the role layer above is described from market structure rather than counted. Therapeutic interest is self-declared by the companies themselves, and private company work is only visible where it has been disclosed.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com